The DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Contraceptive Hormone Use and Cardiovascular Disease
Open accessAbstract
Contraceptive hormones, most commonly prescribed as oral contraceptives (OCs), are a widely utilized method to prevent ovulation, implantation, and, therefore, pregnancy. The Women's Health Initiative demonstrated cardiovascular risk linked to menopausal hormone therapy among women without pre-existing cardiovascular disease, prompting a review of the safety, efficacy, and side effects of other forms of hormone therapy. A variety of basic science, animal, and human data suggests that contraceptive hormones have antiatheromatous effects; however, relatively less is known regarding the impact on atherosclerosis, thrombosis, vasomotion, and arrhythmogenesis. Newer generation OC formulations in use indicate no increased myocardial infarction risk for current users, but a persistent increased risk of venous thromboembolism. There are no cardiovascular data available for the newest generation contraceptive hormone formulations, including those that contain newer progestins that lower blood pressure, as well as the nonoral routes (transdermal and vaginal). Current guidelines indicate that, as with all medication, contraceptive hormones should be selected and initiated by weighing risks and benefits for the individual patient. Women 35 years and older should be assessed for cardiovascular risk factors including hypertension, smoking, diabetes, nephropathy, and other vascular diseases, including migraines, prior to use. Existing data are mixed with regard to possible protection from OCs for atherosclerosis and cardiovascular events; longer-term cardiovascular follow-up of menopausal women with regard to prior OC use, including subgroup information regarding adequacy of ovulatory cycling, the presence of hyperandrogenic conditions, and the presence of prothrombotic genetic disorders is needed to address this important issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [370]
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [370]
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [370]
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [370]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Protective Effects of Estrogen on the Cardiovascular System
Mendelsohn, M. E., & Karas, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402306 · Cited by 3,119
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,917
Estrogen and coronary heart disease in women
Barrett-Connor, E. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460140089033 · Cited by 1,241
Gynecologists (2009) · Cited by 1,035
Chandra, A., Martinez, G. M., Mosher, W. D., Abma, J. C., & Jones, J. (2005) · PsycEXTRA Dataset · doi:10.1037/e414702008-001 · Cited by 957
Chen, Z., Yuhanna, I. S., Galcheva-Gargova, Z., Karas, R. H., Mendelsohn, M. E., & Shaul, P. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5347 · Cited by 924
Jick, H., Jick, S. S., Myers, M. W., Vasilakis‐Scaramozza, C., & Gurewich, V. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91928-7 · Cited by 721
Conjugated Equine Estrogens and Coronary Heart Disease
Hsia, J. A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.357 · Cited by 607
Flagged first, then by citations
1 of the 92 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–286 of 286
Association between the number of pregnancies and hearing loss: NHANES 1999–2018
Lai, H., Wu, J., Chen, Z., Gao, M., & Yang, H. (2025) · BMC Public Health · doi:10.1186/s12889-025-23052-0 · Cited by 1
Sex Differences in Atherosclerosis and its Clinical Complications
Reddy, T. K., Littman, E., Elder-Odame, P., Hussain, Z., & Michos, E. D. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01383-y · Cited by 1
“However, newer generations of oral contraceptives have a lower estrogen formulation and do not increase MI risk, although VTE risk remains [71].”
2025 Egyptian guidelines for the management of dyslipidemia
Reda, A., Taha, H., Badran, H. M., Khamis, H., Kamal, S., Elserafy, A. S., Dawoud, M. H., Elamragy, A. A., Bendary, A., & Shaker, M. M. (2026) · The Egyptian Heart Journal · doi:10.1186/s43044-026-00716-9 · Cited by 1
“Estrogen replacement therapy is not recommended for CV prevention, while low-dose third-generation oral contraceptives are acceptable only in women with normal LDL-C; alternative contraception is advised if LDL-C > 160 mg/dL or with multiple CV risk factors [67].”
Exploring the Antifertility Potential of Stigmasterol: Evidence from a Systematic Review
Susetyarini, E., Wahyono, P., Wahyuni, S., Husamah, H., & Nurrohman, E. (2026) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2026.00276 · Cited by 1
Zhi, W., & Huang, J. (2013) · Chinese Medical Sciences Journal · doi:10.1016/s1001-9294(13)60022-x · Cited by 1
Lee, J., Yoo, J.-Y., Jung, G.-O., & Park, J. Y. (2014) · Journal of Korean society of Dental Hygiene · doi:10.13065/jksdh.2014.14.06.795 · Cited by 1
Women’s Cardiac Health in 2020: A Systematic Review
Sozzi, F. B., Belmonte, M., Schiavone, M., Canetta, C., Gupta, R., & Blasi, F. (2020) · Journal of Cardiac Critical Care TSS · doi:10.1055/s-0040-1718503 · Cited by 1
Primary Prevention and Cardiovascular Risk Assessment in Women
Peterson, L.-A., Freaney, P. M., & Gulati, M. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_10 · Cited by 1
Zhang, J., Shang, X., Liu, Z., Tan, X., He, M., Han, X., & Luo, L. (2022) · Acta Ophthalmologica · doi:10.1111/aos.15267 · Cited by 1
“Contemporary contraceptives are mostly used in reproductive age and contain fairly high oestrogen doses compared with HRT which is mostly used during and after menopause (Shufelt & Bairey Merz, 2009).”
BackgroundRisk Factors for Ischemic Heart Disease in Women
Shen, B., Maeda, U., Eisenberg, S., & Merz, C. N. B. (2022) · Springer eBooks · doi:10.1007/978-0-387-85960-6_7 · Cited by 2
Anticoncepción hormonal en mujeres con hipertensión
Sánchez-Aguirre, F., Fierro-Fuentes, J. M., & Basurto-Acevedo, L. (2024) · Cardiovascular and Metabolic Science · doi:10.35366/115057 · Cited by 1
New treatments: Opportunities and challenges
Drysdale, A. T., Poleshuck, E. L., Ramsey, M. H., & Monk, C. E. (2024) · Seminars in Perinatology · doi:10.1016/j.semperi.2024.151941 · Cited by 1
A INFLUÊNCIA DAS PÍLULAS ANTICONCEPCIONAIS NA PRESSÃO ARTERIAL: UMA REVISÃO INTEGRATIVA
de Carvalho, R. G., Tavares, B. D. B., Lauth, A. C. R., Costa, H. F., dos Santos, M. F. R., & Vilela, L. F. D. C. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i8.15358 · Cited by 1
Leclercq, T., Parrel, S., Mierdl, S., Cottin, Y., & Girard, C. (2014) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2014.04.009 · Cited by 1
Mancia, G., & Fagard, R. H. (2013) · Cited by 1
Place of progestogenic oral contraceptives in gynecological practice
Kuznetsova, I. V. (2019) · Medical alphabet · doi:10.33667/2078-5631-2019-1-1(376)-19-26 · Cited by 1
“Повышение артериального давления — еще один фактор риска сердечно-сосудистых заболеваний, увеличивающий вероятность развития артериального тромбоза у женщин, принимающих КГК [31].”
Hickey, M., & Kaunitz, A. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00018-3 · Cited by 1
Maria, S., Manan, H., Abadi, A., & Theodorus, T. (2020) · Indonesian Journal of Obstetrics and Gynecology · doi:10.32771/inajog.v8i2.1109 · Cited by 1
Multivessel coronary artery vasospasm masquerading as surgical coronary atherosclerotic disease
Singh, N., & Nand, P. (2021) · Journal of Cardiac Surgery · doi:10.1111/jocs.15866 · Cited by 1
Contraceptive Management of Women with Cardiac Disease
Davidson, A., Briller, J. E., & Chor, J. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1233-9_2 · Cited by 1
Aortic thrombus with contraceptive vaginal ring use
Smith, K. L., Bolton, K., Weger, N. S., & Hobbs, R. A. (2023) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1856 · Cited by 1
Blood Pressure: Definition, Diagnosis, and Management
Townsend, R. R., & Steigerwalt, S. P. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-010-6_1 · Cited by 1
“Oral contraceptives ( 50 ) Unknown, usually trivial elevations of blood pressure”
BackgroundToward Optimal Health: Advances in the Cardiovascular Care of Women
Godfrey, J. R., & Wenger, N. K. (2010) · Journal of Women s Health · doi:10.1089/jwh.2010.1957 · Cited by 1
“49 It behooves all clinicians to recommend options that foster smoking cessation among all women who smoke.”
Rabe, T., Goeckenjan, M., Hj, A., Pg, C., Dinger, J. C., Ao, M., Lohr, P. A., Creinin, Sabatini, R., & Strowitzki, T. (2011) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 1
ISCHEMIA IMPAIRS VASODILATION IN SKELETAL MUSCLE RESISTANCE ARTERY
Struthers, K. R. (2011) · doi:10.15368/theses.2011.103 · Cited by 1
Kofole, Z., Haile, D., Solomon, Y., & Girma, E. (2019) · doi:10.21203/rs.2.19624/v1 · Cited by 1
Cardiovasculair Risicomanagement Bij Vrouwen
Maas, A. H. E. M., de Kluiver, E. P., & Lagro‐Janssen, T. (2011) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8782-3_6
Adults with Congenital Heart Disease
Yetman, A., & Webb, G. D. (2012) · doi:10.1002/9781444398786.ch53
Cardiovascular and Other (Except Respiratory) Disorders Related to Smoking Tobacco
Barnoya, J., & Monzon, J. C. (2015) · Progress in respiratory research/Progress in research in emphysema and chronic bronchitis/Progress in respiration research · doi:10.1159/000369368
Contraception et pathologie cardiaque
Plu‐Bureau, G. (2013) · Elsevier eBooks · doi:10.1016/b978-2-294-72785-6.00010-4
Endocrinological Aspects of Atherosclerosis
Freudenberger, T., & Fischer, J. W. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0338-8_28
Identification and Treatment of Women with Familial Hypercholesterolemia
Robinson, J. G. (2012) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-012-0231-7
“Exogenous estrogens increase triglycerides and HDL-C and may lower LDL-C levels, the extent depending on the type of estrogen, route of administration, and coadministration of a progestational agent [54, 55].”
BackgroundQuelle contraception hormonale proposer à une femme hypertendue ?
Bachelot, A., Chakhtoura, Z., & Touraine, P. (2012) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(12)70425-x
Krasznai, Z., & Tóth, P. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-011-2190-5
“The low-dose estradiol and second generation gestagenes are better accepted, when slight cardiovascular risk is present [3].”
BackgroundBeleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Cardiovascular Risk Biomarkers among Oral and Vaginal Hormonal Contraceptive Users
Brandy, K. R. (2011) · University of Minnesota Digital Conservancy (University of Minnesota)
CONTRACETIVOS ORAIS E RISCO TROMBÓTICO
Salazar, A. (2014)
Cardiovascular disease in women. What should we know
Brito, J. A. D., Márquez, I., Feijoo, J., & Luciani, D. (2014)
Rojas, F. (2016) · Clínica e Investigación en Ginecología y Obstetricia · doi:10.1016/j.gine.2016.03.007
Prevention of Ischemic Heart Disease in Women
Orakzai, R. H., SHUFELT, C. L., Shaw, L. J., & Merz, C. N. B. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1366-4.00024-x
Self-citationRobinson, J. G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-384978-6.00063-7
The Interaction of Medical Diseases and Female Physiology
Katz, V. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-323-06986-1.00008-1
Management of Estrogen Deficiency
SHUFELT, C. L., & Waldman, T. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4838-8_29
Self-citationHypertension in Men and Women: Is It Different?
Smulyan, H., & Pannier, B. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5198-2_32
Role of Estrogen and Progesterone in Human Disorders - An Overview
Parikh, D., & Gohil, P. V. (2014)
Fisher, R. (2015) · e-publications@bond (Bond University)
Female Manifestation of Acute Coronary Syndromes
Maas, A. H. E. M., & Merz, C. N. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-54960-6_3
Sudėtinės kontraceptinės tabletės ir hiperkoaguliacija
Adukauskienė, D., & Miliauskienė, V. (2010) · Medicina · doi:10.3390/medicina46040041
Overview of Some Risk Factors in Cardiovascular Disease
Cojocaru, E., Maștaleru, A., Tamba, B.-I., Vasile, R., Tudor, R. C., Ripa, C. V., Cobzaru, R. G., & Leon, M. M. (2017) · InTech eBooks · doi:10.5772/intechopen.69039
“The use of steroid hormonal contraceptives increases two to three times coronary atherosclerosis risk, mainly in smoking female over 35 years [22].”
BackgroundFertility Control in the Cardiac Patient
Briller, J. E., Johnson, M. R., & Roos‐Hesselink, J. W. (2019) · Wiley eBooks · doi:10.1002/9781119409861.ch34
(2010) · Elsevier eBooks · doi:10.1016/b978-2-294-70917-3.50010-1
Cardiovascular Disease in Women: Focus on Lipid Management
Morris, P. B., Aspry, K. E., Watson, K. E., Wild, R. A., & Bittner, V. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_24
Hetea, A., Danciu, B. M., & SIMIONESCU, A. A. (2020) · Obstetrica şi Ginecologia · doi:10.26416/obsgin.68.2.2020.3692
OPÇÕES CONTRACEPTIVAS PARA REDUÇÃO DE EVENTOS TROMBOEMBÓLICOS EM MULHERES DIABÉTICAS
do Carmo, A. D. N., & Lunardelli, A. (2019) · Revista de Patologia do Tocantins · doi:10.20873/uft.2446-6492.2019v6n1p63
BLOOD PRESSURE INCREASES INDUCED BY IATROGENESIS, OVER THE COUNTER SUBSTANCES, AND HERBALS PRODUCTS
Wang, S., & Sander, G. E. (2021) · Medical Research Archives · doi:10.18103/mra.v9i5.2394
“The findings indicate that the AAS group exhibited significant increases in standard cardiovascular measurements compared with the control bodybuilders (25).”
ResultMeasurement of lipids levels and lipase enzyme in women who take birth control pills in Samarra
Science, C. (2021) · Egyptian Journal of Chemistry · doi:10.21608/ejchem.2021.77689.3794
“level, which is related with age and the length of taking the tablets [18], as there was a huge expansion in the TG level and oral estrogen additionally builds TG level [19].”
BackgroundOral Kontraseptif Kullanımının Sağlık ve Serum Mikro Besin Ögesi Seviyeleri Üzerine Etkisi
Dazıroğlu, M. E. Ç., & Akdevelıoğlu, Y. (2021) · Journal of Nutrition and Dietetics · doi:10.33076/2021.bdd.1366
“OK’ler depresyon, migren baş ağrısı gibi çeşitli yan etkilerinin yanı sıra meme ve serviks kanseri (18), felç (17), kardiyovasküler hastalıklar (19), inflamatuvar bağırsak hastalığı (20), iyi huylu veya kötü huylu karaciğer tümörü ve tanı konulmamış anormal vajinal kanama (17) gibi ciddi birtakım sağlık sorunlarının g…”
حسين, ه. ج. (2015) · Maǧallaẗ ǧāmiʻaẗ Karbalāʼ/Maǧallaẗ ǧāmiʻaẗ karbalāʼ
Cauci, S., Francescato, M. P., Colannino, C., Barbina, M., Barbina, G., & Xodo, S. (2020) · doi:10.21203/rs.3.rs-27814/v1
Blood Pressure: Definition, Diagnosis, and Management
Townsend, R. R., & Steigerwalt, S. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-29152-9_1
Sinha, R., Maheshwari, S., Gupta, P. K., Roy, D., & Deepshikha, D. (2022) · Indian Journal of Community Health · doi:10.47203/ijch.2022.v34i02.020
Analysis of Adipokines and some Steroid Hormones in Myocardial Infarction
Yousif, A. M., Ismail, P. A., & Ismail, C. A. (2022) · Baghdad Science Journal · doi:10.21123/bsj.2022.6920
Kirby, N. V., Stachenfeld, N. S., & Alexander, L. M. (2023) · Experimental Physiology · doi:10.1113/ep091174
“…in hypertension risk traditionally associated with oral contraceptive pills, because they instead appear to decrease blood pressure (drospirenone; Shufelt & Bairey Merz, 2009), which makes differentiating between progestin types even more important for future research addressing physiological…”
BackgroundInfluentialMichos, E. D., & WENGER, N. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00032-7
Seghieri, G., Gualdani, E., Franconi, F., Campesi, I., Cianni, G. D., & Francesconi, P. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02143-7
“Moreover, while prior studies did not detect any additive action on cardiovascular risk among women using hormonal contraceptives [10], it has recently been suggested that exposure to CHC, in association with smoking, may modify plasma lipids’ profile possibly predicting a greater risk of atherosclerotic events [11, 1…”
BackgroundFabunmi, O. A., Dludla, P. V., & Nkambule, B. B. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.10.001
SAÚDE CARDIOVASCULAR E DOENÇA ISQUÊMICA NAS MULHERES
de Andrade, A. D., de Moura, A. Q. R., Rosa, D. D., Cavalcante, D. B. L., da Silva, E. I., Santos, G. M., Rolim, J. R. A., & de Santana, T. M. S. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024264p541
Fabunmi, O. A., Dludla, P. V., & Nkambule, B. B. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.02.002
Chesire, B. J., Mogeni, R., & Mwaliko, E. (2024) · Research Square · doi:10.21203/rs.3.rs-4501450/v1
Azizi, N., Eslami, M., Sadrmanesh, O. R., Shakeri, Z., Yarizadeh, H., Azadbakht, L., Larijani, B. A., & Nasli‐Esfahani, E. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-01066-z
“On the other hand, it has been shown that new food indicators such as the healthy drink profile improve the complications of diabetes (including cardiovascular risk factors such as blood pressure, blood lipids, and body weight) [13–15].”
Zheng, L., Zhang, H., Fang, W., & Yang, J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1698533
“Among conservative therapies, GnRH agonists (GnRH-a) are preferred because they suppress estrogen levels, reduce bleeding, and carry a lower thrombotic risk (31, 32).”
Okoth, K., Parry‐Smith, W., Thomas, G. N., Nirantharakumar, K., & Adderley, N. J. (2023) · Figshare · doi:10.6084/m9.figshare.22620248
Hormonal Contraceptive Use, Stress Disorders, and Cardiovascular and Thrombotic Risk in Women
Thomas, J. L., Ellis, R. A., AbiKaram, K., Abohashem, S., Dua, A., Lau, E. S., MacDonald, M. J., Miller, K. K., Pineles, S. L., Rosovsky, R. P. G., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.51878
Al-Anesi, A. A.-Q. F., Abhad, A., Alans, A., Alsumaiee, J. M. A. N., & Hivrale, V. K. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20260954
Vallée, A., Féki, A., Moawad, G., & Ayoubi, J. M. (2026) · Public Health · doi:10.1016/j.puhe.2026.106290
Menopausal Hormone Therapy and Cardiovascular Disease
Safwan, N., Saadedine, M., & Faubion, S. S. (2026) · Springer eBooks · doi:10.1007/978-3-032-18203-6_12
Assessment of Cardiovascular Disease Risk Across the Lifespan
Tapp, D. N., Haygood, D., Tipler, P., Tzoumas, A., & Quesada, O. (2026) · Springer eBooks · doi:10.1007/978-3-032-18203-6_2
Linking combined oral contraceptive use to systemic immune marker profiles: the role of cortisol
Klinger-König, J., van der Auwera, S., Töpfer, P., Ameling, S., Friedrich, N., Völker, U., Völzke, H., Hertel, J., & Grabe, H. J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1796526
“The broad investigation of cytokine, growth factor, and chemokine changes in COC users, as conducted in this study, represents a new research approach (12, 30).”
InfluentialKim, L. Y., Yuk, J., & Kim, B. G. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag380
Hormonelle Kontrazeption bei arteriellem kardiovaskulärem Risiko
Segerer, S. E. (2026) · Gynäkologische Endokrinologie · doi:10.1007/s10304-026-00690-0
Kamaljeet, Minhas, Y., & Kosey, S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02608-0
Metadata
- Authors
- Shufelt, C. L., & Bairey Merz, C. N.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 53
- Issue
- 3
- Pages
- 221-231
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC2660203
- OpenAlex
- W2128055881
- Cited by
- 287
- References
- 92
- Citations by year
- 2026: 14 · 2025: 10 · 2024: 15 · 2023: 17 · 2022: 12 · 2021: 16 · 2020: 24 · 2019: 17 · 2018: 10 · 2017: 11 · 2016: 18 · 2015: 16 · 2014: 17 · 2013: 22 · 2012: 18
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hv068164-006, n01hv068162-009, n01hv068161-005, n01hv068163-006)
- National Heart, Lung, and Blood Institute (N01-HV68162, N01 HV068162, N01HV68163, N01 HV068164, N01- HV-068161, N01 HV068163)
- National Center for Research Resources (MO1-RR00425, M01RR000425)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- oral contraceptives, cardiovascular risk, hormone replacement therapy, atherosclerosis, thrombosis, venous thromboembolism, myocardial infarction, progestins, vaginal ring, cardiovascular risk assessment, Women's Health Initiative
- MeSH terms
- Adult, Age Factors, Animals, Cardiovascular Diseases, Contraceptives, Oral, Hormonal, Disease Models, Animal, Female, Humans, Middle Aged, Thromboembolism, United States, Cohort Studies, Incidence, Practice Guidelines as Topic, Premenopause, Postmenopause, Risk Assessment, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
